BioWorld

Nov. 6, 2007

Deaths End Novacea's Prostate Cancer Trial

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today) Read More

Lead Therapeutics' Series A: $17M For Research In China

Immune Proteins 'Moonlight' In Brain Development, Repair

Favrille Adding $21M Via Direct Offering For FavId

Liver Disease Roundup

Other News To Note

American Heart Assoc. Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 13, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026